Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, and Synerx Pharma, LLC, announced today the launch of Fomepizole Injection, the generic equivalent of Antizol(R) from Paladin Labs, Inc.
"The addition of Fomepizole to Bioniche's product offering further broadens our base of niche injectables," said George Zorich, President, US Operations for Bioniche Pharma.
Bioniche Pharma and Synerx Pharma entered into a definitive agreement whereby Bioniche Pharma has the rights to market and distribute Fomepizole in the United States.
Bioniche will supply Fomepizole Injection in 1.5g /1.5 mL vials.
Supply chain assessment and management, optimizing pharmaceutical supply chains